Xymoheal D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the resolution of inflammation and edema by enhancing the absorption of inflammatory exudates. Rutoside, a bioflavonoid, strengthens capillary walls and reduces capillary permeability, thereby minimizing bruising and swelling. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to decreased synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these components makes Xymoheal D Tablet particularly effective in managing acute musculoskeletal conditions such as sprains, strains, contusions, and postoperative inflammation. It is also beneficial in reducing pain and swelling associated with chronic inflammatory disorders. Xymoheal D should be administered under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, peptic ulcer disease, or bleeding disorders. Adherence to prescribed dosage is essential to minimize adverse effects, which may include gastrointestinal discomfort, allergic reactions, or bleeding tendencies. Overall, Xymoheal D Tablet offers a comprehensive therapeutic approach to inflammation and pain management through its multimodal mechanism of action.